SELLAS Life Sciences Group, Inc.

Analysis for Ticker: SLS

SELLAS Life Sciences Group Inc is a clinical stage biopharmaceutical company that claims to develop cancer treatments like Galinpepimut-S and SLS009. In reality, the company has burned through 275$ million since its inception without ever selling a single product. Its actual business model is not medicine, but the continuous manufacturing and selling of its own stock to pay its bills. Think of it like a bakery that never sells bread but survives by constantly selling pieces of the oven to neighbors who hope a loaf will eventually appear. The math is a disaster because the bakery is almost entirely owned by people who are just waiting to sell their piece of the oven to the next person, while the people running the bakery take the cash for themselves. The bleeding started years ago and has only accelerated. In 2023, the company lost 37,34$ million, followed by a 30,88$ million loss in 2024. This money was spent on royalties to Memorial Sloan Kettering Cancer Center, 10$ million to license a drug from GenFleet Therapeutics, and payments to contractors like Polypeptide Group. Their only hope for income was a 10,5$ million payment from 3D Medicines, but that partnership collapsed into a legal fight over unpaid milestones. To stay alive, the company turned into a share printing factory. In 01/2025, they sold 8,2 million shares and attached 19,68 million warrants, which are basically coupons that let investors buy more shares later at a fixed price.